Medicine
Ethosuximide 250 mg/5 mL oral solution
Ethosuximide 250 mg/5 mL oral solution is a generic prescription medicine for oral use, made by 4 labelers, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Protect from freezing and light. Store at 20° to 25°C (68° to 77°F).
Key facts
- Active ingredient (INN)
- Ethosuximide
- Brand
- Sold under the generic name
- Strength
- 250 mg/5 mL
- Dosage form
- Oral solution
- Route
- Oral
- Packs
- 2 trays, 473 mL, 1 bottle and 2 more
- Manufacturers
- Mylan PharmaceuticalsChartwell Governmental & Specialty RXChartwell RXPAI Pharma
- Origin register
- US FDA, United States
- Storage
- Protect from freezing and light. Store at 20° to 25°C (68° to 77°F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- N03AD01 Ethosuximide
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 22 November 2000
- Identifiers
- RxCUI 251322DailyMed set ID a825265d-ace9-4463-a16d-f6d5e1e31188, 8a5cc930-0b36-48a8-9ad0-de633b208742, 19c924c2-f558-4c78-9277-2d7e0df2f505 +1NDC 68999-064, 0121-0670, 59762-2350 +1Application ANDA040506, ANDA040253, ANDA080258
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
Packs from every labeler of this generic presentation.
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 2 tray in 1 box / 10 cup in 1 tray / 5 mL in 1 cup | 68999-064-24 | Chartwell Governmental & Specialty RX | 9 June 2026 |
| 473 mL in 1 bottle | 62135-064-47 | Chartwell RX | 20 May 2026 |
| 1 bottle, plastic in 1 carton / 474 mL in 1 bottle, plastic | 59762-2350-6 | Mylan Pharmaceuticals | 21 February 2020 |
| 1 bottle, plastic in 1 carton / 474 mL in 1 bottle, plastic | 59762-2350-7 | Mylan Pharmaceuticals | 1 July 2022 |
| 473 mL in 1 bottle | 0121-0670-16 | PAI Pharma | 22 November 2000 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 2 November 1960 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Alternatives
Other makers and brands of Ethosuximide 250 mg/5 mL oral solution.
Other strengths and forms of Ethosuximide
Clinical summary
Ethosuximide is an anti-epileptic agent indicated for the control of absence (petit mal) epilepsy. It is available as capsules and oral solution. MedsAcross supplies Ethosuximide for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about EthosuximideFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Zarontin prescribing information (Parke-Davis) · U.S. National Library of Medicine, DailyMed
Need Ethosuximide 250 mg/5 mL oral solution for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.